Gross Profit Trends Compared: Bausch Health Companies Inc. vs Amphastar Pharmaceuticals, Inc.

Bausch vs. Amphastar: A Decade of Profit Trends

__timestampAmphastar Pharmaceuticals, Inc.Bausch Health Companies Inc.
Wednesday, January 1, 2014512560006008900000
Thursday, January 1, 2015773470007853800000
Friday, January 1, 20161041890007063000000
Sunday, January 1, 2017907950006176000000
Monday, January 1, 20181069850006029000000
Tuesday, January 1, 20191319230006251000000
Wednesday, January 1, 20201433400005778000000
Friday, January 1, 20211997390006040000000
Saturday, January 1, 20222488600005760000000
Sunday, January 1, 20233511210006198000000
Loading chart...

Unleashing insights

Gross Profit Trends: A Tale of Two Companies

Bausch Health vs. Amphastar Pharmaceuticals

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This analysis compares the gross profit trajectories of Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc. from 2014 to 2023.

Bausch Health, a giant in the sector, consistently reported robust profits, peaking in 2015 with a 30% higher gross profit than its 2023 figures. Despite fluctuations, Bausch maintained an average annual gross profit of approximately $6.3 billion.

Conversely, Amphastar Pharmaceuticals, a smaller player, demonstrated impressive growth. From a modest start in 2014, Amphastar's gross profit surged by nearly 600% by 2023, reflecting its strategic market positioning and expansion efforts.

This comparison highlights the diverse strategies and market dynamics within the pharmaceutical industry, offering valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025